SHP-1 expression accounts for resistance to imatinib treatment in Philadelphia chromosome-positive cells derived from patients with chronic myeloid leukemia

Blood

Volumn 118, Issue 13, 2011, Pages 3634-3644

  Esposito, Nicola ^a,b   Colavita, Irene ^a,b   Quintarelli, Concetta ^a,b   Sica, Agostino Rodeo ^a,b   Peluso, Anna Lucia ^a,b   Luciano, Luigia ^b   Picardi, Marco ^a,b   Del Vecchio, Luigi ^a,b   Buonomo, Tonia ^a,b   Hughes, Timothy P ^c   White, Deborah ^c   Radich, Jerald P ^d   Russo, Domenico ^e   Branford, Susan ^c   Saglio, Giuseppe ^f   Melo, Junia V ^c   Martinelli, Rosanna ^a,g   Ruoppolo, Margherita ^a,b   Kalebic, Thea ^h   Martinelli, Giovanni ⁱ   Pane, Fabrizio ^a,b   more..

^a CEINGE BIOTECNOLOGIE AVANZATE   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^c INSTITUTE OF MEDICAL AND VETERINARY SCIENCE   (Australia)

^d Fred Hutchinson Cancer Research Center   (United States)

^e Ospedali Civili   (Italy)

^f UNIVERSITY OF TURIN   (Italy)

^g UNIVERSITY OF SALERNO   (Italy)

^h NOVARTIS PHARMA AG   (Switzerland)

ⁱ UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; IMATINIB; MESSENGER RNA; PROTEIN TYROSINE PHOSPHATASE SHP 1; PROTEIN TYROSINE PHOSPHATASE SHP 2; STAT3 PROTEIN; TYROSINE KINASE RECEPTOR;

ADULT; AGED; ARTICLE; CELL VIABILITY; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; DRUG ACTIVITY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; PHILADELPHIA 1 CHROMOSOME; PHILADELPHIA CHROMOSOME POSITIVE CELL; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION;

EID: 80053373694     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-03-341073     Document Type: Article

References (43)

1. Melo JV, Barnes DJ. Chronic myeloid leukaemia as a model of disease evolution in human cancer. Nat Rev Cancer. 2007;7(6):441-453. (Pubitemid 46823444)
2. O'Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2003;348(11):994-1004. (Pubitemid 36302244)
3. Druker BJ, Guilhot F, O'Brien SG, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006;355(23):2408-2417. (Pubitemid 44903745)
4. Soverini S, Colarossi S, Gnani A, et al. Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphiapositive patients: by the GIMEMAWorking Party on Chronic Myeloid Leukemia. Clin Cancer Res. 2006;12(24):7374-7379. (Pubitemid 46095411)
5. Mahon FX, Belloc F, Lagarde V, et al. MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models. Blood. 2003;101(6):2368-2373. (Pubitemid 36304670)
6. Gambacorti-Passerini C, Barni R, le Coutre P, et al. Role of alpha1 acid glycoprotein in the in vivo resistance of human BCR-ABL(+) leukemic cells to the abl inhibitor STI571. J Natl Cancer Inst. 2000;92(20):1641-1650.
7. Donato NJ, Wu JY, Stapley J, et al. BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571. Blood. 2003;101(2):690-698. (Pubitemid 36077594)
8. Wang N, Li Z, Ding R, et al. Antagonism or synergism. Role of tyrosine phosphatases SHP-1 and SHP-2 in growth factor signaling. J Biol Chem. 2006;281(31):21878-21883. (Pubitemid 44181891)
9. Chong ZZ, Maiese K. The Src homology 2 domain tyrosine phosphatases SHP-1 and SHP-2: diversified control of cell growth, inflammation, and injury. Histol Histopathol. 2007;22(11):1251-1267. (Pubitemid 47470319)
10. Araki T, Nawa H, Neel BG. Tyrosyl phosphorylation of Shp2 is required for normal ERK activation in response to some, but not all, growth factors. J Biol Chem. 2003;278(43):41677-41684. (Pubitemid 37310425)
11. Maroun CR, Naujokas MA, Holgado-Madruga M, Wong AJ, Park M. The tyrosine phosphatase SHP-2 is required for sustained activation of extracellular signal-regulated kinase and epithelial morphogenesis downstream from the met receptor tyrosine kinase. Mol Cell Biol. 2000;20(22):8513-8525.
12. Montagner A, Yart A, Dance M, Perret B, Salles JP, Raynal P.Anovel role for Gab1 and SHP2 in epidermal growth factor-induced Ras activation. J Biol Chem. 2005;280(7):5350-5360. (Pubitemid 40280009)
13. Edouard T, Montagner A, Dance M, et al. How do Shp2 mutations that oppositely influence its biochemical activity result in syndromes with overlapping symptoms? Cell Mol Life Sci. 2007;64(13):1585-1590. (Pubitemid 47036934)
14. Neel BG. Structure and function of SH2-domain containing tyrosine phosphatases. Semin Cell Biol. 1993;4(6):419-432.
15. Tartaglia M, Niemeyer CM, Fragale A, et al. Somatic mutations in PTPN11 in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia. Nat Genet. 2003;34(2):148-150. (Pubitemid 36666923)
16. Loh ML, Vattikuti S, Schubbert S, et al. Mutations in PTPN11 implicate the SHP-2 phosphatase in leukemogenesis. Blood. 2004;103(6):2325-2331. (Pubitemid 38326253)
17. Tartaglia M, Martinelli S, Cazzaniga G, et al. Genetic evidence for lineage-related and differentiation stage-related contribution of somatic PTPN11 mutations to leukemogenesis in childhood acute leukemia. Blood. 2004;104(2):307-313. (Pubitemid 38900008)
18. Chan G, Kalaitzidis D, Usenko T, et al. Leukemogenic Ptpn11 causes fatal myeloproliferative disorder via cell-autonomous effects on multiple stages of hematopoiesis. Blood. 2009;113(18):4414-4424.
19. Chim CS, Fung TK, Cheung WC, Liang R, Kwong YL. SOCS1 and SHP1 hypermethylation in multiple myeloma: implications for epigenetic activation of the Jak/STAT pathway. Blood. 2004;103(12):4630-4635. (Pubitemid 38745995)
20. Oka T, Ouchida M, Koyama M, et al. Gene silencing of the tyrosine phosphatase SHP1 gene by aberrant methylation in leukemias/lymphomas. Cancer Res. 2002;62(22):6390-6394. (Pubitemid 35364092)
21. Zhang Q, Raghunath PN, Vonderheid E, Odum N, Wasik MA. Lack of phosphotyrosine phosphatase SHP-1 expression in malignant T-cell lymphoma cells results from methylation of the SHP-1 promoter. Am J Pathol. 2000;157(4):1137-1146.
22. Han Y, Amin HM, Frantz C, et al. Restoration of shp1 expression by 5-AZA-2′-deoxycytidine is associated with downregulation of JAK3/STAT3 signaling in ALK-positive anaplastic large cell lymphoma. Leukemia. 2006;20(9):1602-1609. (Pubitemid 44264104)
23. Uhm KO, Lee ES, Lee YM, et al. Differential methylation pattern of ID4, SFRP1, and SHP1 between acute myeloid leukemia and chronic myeloid leukemia. J Korean Med Sci. 2009;24(3):493-497.
24. Amin HM, Hoshino K, Yang H, Lin Q, Lai R, Garcia-Manero G. Decreased expression level of SH2 domain-containing protein tyrosine phosphatase-1 (Shp1) is associated with progression of chronic myeloid leukaemia. J Pathol. 2007;212(4):402-410. (Pubitemid 47099017)
25. Kharbanda S, Bharti A, Pei D, et al. The stress response to ionizing radiation involves c-Abldependent phosphorylation of SHPTP1. Proc Natl Acad Sci U S A. 1996;93(14):6898-6901. (Pubitemid 26243471)
26. Bruecher-Encke B, Griffin JD, Neel BG, Lorenz U. Role of the tyrosine phosphatase SHP-1 in K562 cell differentiation. Leukemia. 2001;15(9):1424-1432. (Pubitemid 32785312)
27. Neviani P, Santhanam R, Trotta R, et al. The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR/ABL-regulated SET protein. Cancer Cell. 2005;8(5):355-368. (Pubitemid 41579831)
28. Baccarani M, Cortes J, Pane F, et al. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol. 2009;27(35):6041-6051.
29. Brasher BB, van Etten RA. c-Abl has high intrinsic tyrosine kinase activity that is stimulated by mutation of the Src homology 3 domain and by autophosphorylation at two distinct regulatory tyrosines. J Biol Chem. 2000;275(45):35631-35637.
30. Colavita I, Esposito N, Martinelli R, et al. Gaining insights into the Bcr-Abl activity-independent mechanisms of resistance to imatinib mesylate in KCL22 cells: a comparative proteomic approach. Biochim Biophys Acta. 1804(10):1974-1987.
31. Chabot GG, Momparler RL. Effects of 5-aza-2′-deoxycytidine on survival and cell cycle progression of L1210 leukemia cells. Leuk Res. 1986;10(5):533-537. (Pubitemid 16118157)
32. Mohi MG, Neel BG. The role of Shp2 (PTPN11) in cancer. Curr Opin Genet Dev. 2007;17(1):23-30. (Pubitemid 46131442)
33. Mahon FX, Deininger MW, Schultheis B, et al. Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance. Blood. 2000;96(3):1070-1079. (Pubitemid 30616875)
34. Bruennert D, Czibere A, Bruns I, et al. Early in vivo changes of the transcriptome in Philadelphia chromosome-positive CD34+ cells from patients with chronic myelogenous leukaemia following imatinib therapy. Leukemia. 2009;23(5):983-985.
35. Khoury JD, Rassidakis GZ, Medeiros LJ, Amin HM, Lai R. Methylation of SHP1 gene and loss of SHP1 protein expression are frequent in systemic anaplastic large cell lymphoma. Blood. 2004;104(5):1580-1581. (Pubitemid 39166542)
36. Lim YM, Wong S, Lau G, Witte ON, Colicelli J. BCR/ABL inhibition by an escort/phosphatase fusion protein. Proc Natl Acad Sci U S A. 2000;97(22):12233-12238.
37. Liedtke M, Pandey P, Kumar S, Kharbanda S, Kufe D. Regulation of Bcr-Abl-induced SAP kinase activity and transformation by the SHPTP1 protein tyrosine phosphatase. Oncogene. 1998;17(15):1889-1892. (Pubitemid 28488456)
38. Goga A, McLaughlin J, Afar DE, Saffran DC, Witte ON. Alternative signals to RAS for hematopoietic transformation by the BCR-ABL oncogene. Cell. 1995;82(6):981-988.
39. Dance M, Montagner A, Salles JP, Yart A, Raynal P. The molecular functions of Shp2 in the Ras/Mitogen-activated protein kinase (ERK1/2) pathway. Cell Signal. 2008;20(3):453-459.
40. Samanta AK, Chakraborty SN, Wang Y, et al. Jak2 inhibition deactivates Lyn kinase through the SET-PP2A-SHP1 pathway, causing apoptosis in drug-resistant cells from chronic myelogenous leukemia patients. Oncogene. 2009;28(14):1669-1681.
41. Coppo P, Flamant S, De Mas V, et al. BCR-ABL activates STAT3 via JAK and MEK pathways in human cells. Br J Haematol. 2006;134(2):171-179. (Pubitemid 43893908)
42. Lu W, Gong D, Bar-Sagi D, Cole PA. Site-specific incorporation of a phosphotyrosine mimetic reveals a role for tyrosine phosphorylation of SHP-2 in cell signaling. Mol Cell. 2001;8(4):759-769. (Pubitemid 33030210)
43. Vila-Coro AJ, Rodriguez-Frade JM, Martin DeAna A, Moreno-Ortiz MC, Martinez AC, Mellado M. The chemokine SDF-1alpha triggers CXCR4 receptor dimerization and activates the JAK/STAT pathway. FASEB J. 1999;13(13):1699-1710. (Pubitemid 29473332)